Kymera Therapeutics (KYMR) Research & Development (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Research & Development data on file, last reported at $98.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $98.2 million, up 22.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $334.5 million (up 23.11% YoY), and the FY2025 annual result was $316.6 million, up 31.77% from the prior year.
• Research & Development rose to $98.2 million in Q1 2026 per KYMR's latest filing, from $83.8 million in the prior quarter.
• Over five years, Research & Development peaked at $98.2 million in Q1 2026 and troughed at $35.9 million in Q1 2022.
• A 5-year average of $59.3 million and a median of $53.0 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development gained 9.66% in 2023, then surged 64.39% in 2025.
• A 5-year view of Research & Development shows it stood at $43.1 million in 2022, then rose by 22.81% to $53.0 million in 2023, then soared by 35.58% to $71.8 million in 2024, then grew by 16.73% to $83.8 million in 2025, then grew by 17.1% to $98.2 million in 2026.
• Business Quant data shows KYMR's Research & Development at $98.2 million in Q1 2026, $83.8 million in Q4 2025, and $74.1 million in Q3 2025.